MELANOMA BRAF V600E/K MUTATED
Clinical trials for MELANOMA BRAF V600E/K MUTATED explained in plain language.
Never miss a new study
Get alerted when new MELANOMA BRAF V600E/K MUTATED trials appear
Sign up with your email to follow new studies for MELANOMA BRAF V600E/K MUTATED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to boost immune attack on tough melanoma
Disease control OngoingThis study tests a new drug, BI-1607, added to two existing immunotherapy drugs (ipilimumab and pembrolizumab) for people with advanced melanoma that has spread or can't be removed. The goal is to see if the combination is safe and helps the immune system fight cancer better. Abo…
Matched conditions: MELANOMA BRAF V600E/K MUTATED
Phase: PHASE1, PHASE2 • Sponsor: BioInvent International AB • Aim: Disease control
Last updated May 17, 2026 08:12 UTC
-
Melanoma study pulled before start: local attack on resistant tumors never tested
Disease control TerminatedThis study planned to test whether adding surgery, radiation, or electrochemotherapy could help control melanoma spots that did not shrink with the targeted drug combo encorafenib + binimetinib. It was designed for adults with BRAF-mutated melanoma who had been on the drugs for a…
Matched conditions: MELANOMA BRAF V600E/K MUTATED
Phase: PHASE4 • Sponsor: SRH Wald-Klinikum Gera GmbH • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC